Please assess the completion status of the following clinical trial:

Trial Title: CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of acute pancreatitis established by the presence of abdominal pain consistent with acute pancreatitis and 1 of the following 2 criteria:~   1. Serum lipase and/or serum amylase \> 3 times the upper limit of normal (ULN);~  2. Characteristic findings of acute pancreatitis on abdominal imaging;~2. A SpO2 \<96% with a FiO2 of 21% (room air) to 27%, or a SpO2 \<97% with a FiO2 ≥28%;~3. Diagnosis of SIRS, defined by the presence of at least 2 of the following 4 criteria:~   1. Temperature \< 36°C or \> 38°C;~  2. Heart rate \> 90 beats/minute;~  3. Respiratory rate \>20 breaths/minute or arterial carbon dioxide tension (PaCO2) \<32 mmHg;~  4. White blood cell count (WBC) \>12,000 mm3, or \<4,000 mm3, or \> 10% immature (band) forms;~4. No evidence of pancreatic necrosis on contrast-enhanced computed tomography (CECT performed in the 18 hours prior to consent or after consent and before Day 1;~5. Adults ≥ 18 years of age;~6. A female patient of child bearing potential who is sexually active with a male partner must be willing to practice acceptable methods of birth control for 365 days after the last dose of CM4620-IE;~7. A male patient who is sexually active with a female partner of childbearing potential must be willing to practice acceptable methods of birth control for 365 days after the last dose of CM4620-IE and must not donate sperm for 365 days.~8. Willing and able to, or have a legal authorized representative (LAR) that is willing and able to, provide informed consent to participate, and to cooperate with all aspects of the protocol.~Exclusion Criteria:~1. Any concurrent clinical condition that a study physician believes could potentially pose an unacceptable health risk to the patient while involved in the study, including a CV SOFA score of 4 at the time of screening, or may limit expected survival to \<6 months;~2. Suspected presence of cholangitis in the judgment of the treating investigator;~3. ERCP performed in the previous 7 days;~4. Any malignancy being treated with chemotherapy or immunotherapy;~5. Any autoimmune disease being treated with immunosuppressive medication or immunotherapy;~6. History of:~   1. Acute pancreatitis with pancreatic necrosis on Contrast-Enhanced Computed Tomography (CECT) of the pancreas;~  2. Chronic pancreatitis, pancreatic necrosis or necrosectomy, or pancreatic enzyme replacement therapy;~  3. Biopsy proven cirrhosis, portal hypertension, hepatic failure/hepatic encephalopathy;~  4. Known hepatitis B or C, or HIV;~  5. History of organ or hematologic transplant;~  6. Resuscitated cardiac arrest, myocardial infarction, revascularization, cardiovascular accident (CVA) in the 30 days prior to Day 1;~7. Current renal replacement therapy;~8. Current known abuse of cocaine or methamphetamine;~9. Known to be pregnant or are nursing;~10. Participated in another study of an investigational drug or therapeutic medical device in the 30 days prior to Day 1;~11. History of allergy to eggs or known hypersensitivity to any components of CM4620-IE.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose Group (Type: EXPERIMENTAL): Phase 1: Cohorts 1 \& 2 will consist of 4 female and 4 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
- High Dose Group (Type: EXPERIMENTAL): Phase 2: Cohorts 3 \& 4 will consist of 8 female and 8 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
- Standard of Care (Type: NO_INTERVENTION): For all cohorts, patients will be randomized 3:1 to CM4620-IE plus standard of care versus standard of care alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).